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Table 1
Variable Pre-PTRAS Post-PTRAS p
SP 153.0417.07 124.7511.40 <0.001
Men 146.9215.88 124.089.00 <0.001
Women 158.3316.76 125.3313.43 <0.001
DP 92.5010.76 77.548.23 <0.001monitoring and no serious arrhythmia was detected. The mean scores of the domains
of the SF-36 namely, physical functioning, role functioning, social functioning, mental
health, vitality, pain and general health were similar in ASD patients and the control
group (Table 1). The only sociodemographic variable that was found to be associated
with quality of life outcome parameters in the patient group was educational level.
Higher educational level was signiﬁcantly associated with better mental health and
better general health perception (r¼0.248, p¼0.04; r¼0.315, p¼0.008, respectively).
Conclusıon: Adult patients who underwent percutaneous ASD closure perceive their
quality of life as good as their healty counterparts.Table 1
ASD patiens Control group p value
Physical
functioning
73.820.7 73.927.3 0.97
Role physical 67.441.2 69.240.2 0.79
Pain 64.325.5 61.725.6 0.55
General health 60.525.3 62.320.8 0.64
Vitality 56.321.2 55.220.9 0.76
Social functioning 74.922.9 73.322.8 0.69
Role emotional 63.639.9 62.241.9 0.84
Mental health 63.719.0 63.617.5 0.96
The SF-36 domain scores in ASD patients and the control group.
Men 87.318.81 76.317.93 0.001
Women 97.0010.49 78.608.60 <0.001
Number of drug 3.710.85 2.460.69 <0.001
Men 3.850.80 2.310.75 <0.001
Women 3.600.91 2.600.63 0.006
Creatinine 1.130.31 1.130.31 0.150
Men 1.410.53 1.170.32 0.088
Women 1.150.42 1.100.30 0.767
eGFR 60.8935.21 61.7521.08 0.899
Men 62.7731.31 70.6922.94 0.300
Women 59.2739.30 54.0016.37 0.632
Table 2: Pre-Percutaneous transluminal renal angioplasty with stent (PTRAS) and at 6 month
follow up results of blood pressure, medications, creatinine and estimated glomerular ﬁltra-
tion rate. Abbrevations: PTRAS, percutaneous transluminal renal artery stenting; SP, systolic
blood pressure; DP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate.
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Background and AIM: Metabolic syndrome (MS) is associated with cardiovascular
mortality and morbidity in patients with acute coronary syndrome. The purpose of this
studywas to evaluate the impact ofMSon long-termclinical outcomes in patientswithpure
non-ST segment myocardial infarction (NSTEMI) or unstable angina pectoris (USAP).
Methods-Results: We prospectively enrolled 310 consecutive NSTEMI/USAP patients
(74 females;meanage, 59.311.9years).The studypopulationwasdivided into twogroups:
MS(+) and MS(-). The clinical outcomes of the patients were followed for up to 3 years.
Increased 3-year cardiovascular mortality and reinfarction were observed in the
MS(+) group, as compared to theMS(-) group (15 vs. 3.4%, p¼0.001, and 22.2 vs. 8.3%,
p¼0.001, respectively). Hospitalization rates for heart failure and stroke were not
signiﬁcantly different between the two groups on follow-up. By a Cox multivariate
analysis, a signiﬁcant association was noted between MS and the adjusted risk of 3-year
cardiovascular mortality (odds ratio 3.4, 95% conﬁdence interval, 1.24-9.1, p¼0.02).
Conclusıon: These results suggest that MS is associated with an increased risk of 3-
year cardiovascular mortality and reinfarction in patients with NSTEMI/USAP.
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Objectıves: Atherosclerotic renal artery stenosis (ARAS) is associated with uncon-
trolled hypertension and chronic renal failure. The aim of this study is to evaluate the
inﬂuence of gender and presence of chronic renal failure on the outcomes of percu-
taneous transluminal renal artery stenting (PTRAS) due atherosclerosis.
Methods: A total of 28 ARAS patients underwent PTRAS and 36 stents were placed.
Basal characteristics, laboratory data and blood pressure of patients were recorded.
The differences between genders and improvement/deterioration of renal functions
and blood pressure were analyzed. The predictors of outcomes were determined.
Results: Baseline characteristics were similar between men and women. Signiﬁcant
improvement of systolic and diastolic blood pressure control was achieved after
PTRAS (153.0417.07 mmHg vs. 124.7511.40 mmHg, p¼0.001 and 92.5010.76
mmHg vs. 77.548.23 mmHg, p<0.001, respectively) (Table-1). Although mean
estimated glomerular ﬁltration rate (eGFR) and creatinine levels did not signiﬁcantly
improved at 6 month follow up visit in compared to baseline values, of the 28 patients
13 (46.4%) patients had improvement of renal functions.
Conclusıon: Our results suggests that PTRAS is a safe procedure and may offer blood
pressure control but beneﬁcial effects of PTRAS on renal function may be anticipated
in selected group of patients, especially those with a low eGFR.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTPP-359
Comparison of Carvedilol, Nebivolol and Metoprolol for the Prevention of
Contrast Induced Nephropathy
Çagdas¸ Akgüllü, Ufuk Eryılmaz, Ahmet Huyut, Tolga Hekim, Hasan Güngör,
Cemil Zencir
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Background: Metoprolol, carvedilol and nebivolol were different beta blockers with
different properties. In the literature there are various studies evaluating renal effects
of these beta blockers under different conditions. However, to the best of our
knowledge there is not any study comparing preventive effects of these three beta
blockers with each other against contrast induced nephropathy (CIN).
Aım: We aimed to investigate and compare the probable prophylactic effects of three
beta blocker agents, carvedilol, nebivalol and metoprolol against CIN.
Method: 184 patients who were hospitalized for further evaluation with coronary
angiography and have been using beta blocker agent (50 mg metoprolol, 25 mg
carvedilol or 5 mg nebivolol) at least for a week were enrolled to the study. Exclusion
criteria included dialysis patients, recent exposure to contrastmedia or a nephrotoxic
agent within 7 days before the study, urgent percutaneous coronary intervention (PCI),
requiring loop diuretics, theophylline/ aminophylline, dopamine throughout the study,
hemodynamically unstable patients. Patients were divided into three groups: meto-
prolol (M) (64 patient), nebivolol (N) (60 patient), carvedilol (C) (60 patient). All
groups were hydrated before and after the coronary procedure for 12 hours with the
rate of 1 ml/kg/hour intravenous isotonic saline. Serum cretainine (Cr) levels were
checked in the second and ﬁfth days of the study. The primary end point was the
occurence of CIN. We deﬁned CIN as an increase 0.5 mg/dL and/or 25% in serum
creatinine (SCr) concentration at day 2 and/or day 5 of the procedure.
Results: The distribution of various characteristics of the participants is shown in
Table 1and Table 2. Seven (10.9%) patients in group M developed CIN, as did 5
patients (8.3%) in group N and 2 patients (3.3%) in group C. Patients in carvedilol
group developed less CIN, however the difference with the group C and the others
did not reach statistical signiﬁcance (p¼0.283) (Figure 1). Changes in mean Cr
level from baseline to day 2 and day 5 were not statistically signiﬁcant in all groups.
Conclusıon: If there is indication for a beta blocker therapy before the coronary
angiography procedure, although the comperative results with metoprolol and nebi-
volol did not reach statistical signiﬁcance, this study demonstrated a weak evidence
favouring against carvedilol prescription as it would be a better choice for the
prevention of CIN.ERS C223
Table 1
metoprolol nebivalol carvedilol p
Male 38 (59.4%)a 21 (35%)b 32 (53.3%)a.b 0,02
Female 26 (40.6%)a 39 (65%)b 28 (46.7%)a.b 0.02
Diabetes
Mellitus
17 (26.6%) 20 (33.3%) 14 (23.3%) 0.494
Hypertension 51 (79.7%)a 33 (55%)b 36 (60%)b 0.008
Hyperlipidemia 29 (45.3%)a 9 (15%)b 14 (23.3%)b 0.001
Family History
of coronary
heart disease
9 (14.1%) 3 (5%) 5 (8.3%) 0.228
Smoking 29 (45.3%)a 14 (23.3%)b 25 (41.7%)a.b 0.023
Statin 33 (51.6%) 25 (41.7%) 28 (46.7%) 0.532
ACE 27 (42.2%) 16 (26.7%) 16 (26.7%) 0.114
ARB 18 (28.1%) 14 (23.3%) 16 (26.7%) 0.871
Tiazide 5 (7.8%) 6 (10%) 6 (10%) 0.902
Trimetazidin 3 (4.7%) 4 (6.7%) 3 (5%) 0.925
Metformine 10 (15.6%) 12 (20%) 7 (11.7%) 0.466
CIN 7 (10.9%) 5 (8.3%) 2 (3.3%) 0.283
Categorical distributions of various characteristics of the participants
Table 2
Metoprolol Nebivolol Carvedilol p
Age y 59.89.74a 58.2310.6a.b 54.5510.23b 0.014
BMI kg/m2 30.514.68 31.2814.18 29.934.77 0.711
EF % 58.149.88 60.459.96 57.7510.1 0.107
Mehran score 3.532.86 3.852.93 3.373.02 0.515
Total contrast
dose ml
127.9773.66a 99.6739.44a 104.6779.86b 0.009
Creatinine
clearance
89.1220.46 94.6425.98 96.6926.20 0.2
Basal
creatinine
0.890.21a 0.80.2b 0.80.16b 0.023
Second day
creatinine
0.920.26a 0.840.22a 0.820.17b 0.029
Fiﬁth day
creatinine
0.900.19a 0.810.20b 0.810.14b 0.008
HB 13.291.48 12.861.34 12.92.17 0.290
LDL 116.5434.5 115.5234.3 119.2141.1 0.855
TG 161.2389.2 168.27151.5 180.38122.3 0.753
Glukose 114.7237.3 118.9757.8 116.8753.9 0.652
Numerical data of the distribution of various characteritics of participants
Demographic charecteristics
Average age (years) 61,6 (36-85)
Diyabetes Mellitus (%) 56,0
Hyperlipidemia (%) 56,0
Cigarette (%) 37,8
Coronary Artery Disease (%) 87,8
Hypertension (%) 70,7
Gender (male %) 87,1
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Objectıves: Our goal is to evaluate the effectiveness, reliability, advantages and the
results of early-to-mid-term of percutaneous treatment of lower extremity strictures.
Background: Technological advances in the past decade have shifted revasculari-
zation strategies from traditional open surgical approaches toward lower-morbidity
percutaneous endovascular treatments for patients with lower extremity peripheral
arterial disease (PAD). The role of endovascular interventions is also expanding in the
treatment of limb-threatening ischemia. Especially in chronic limb ischemia and foot
ulcers, diabetic patients with inoperable, there is growing interest below the knee
interventions.
Methods: Between May 2011 and May 2013, 85 patients with stenosis of the lower
limb arteries (iliac-femoral-popliteal-below the knee) and treated percutaneously,
enrolled in the study. Although medical therapy, patients with intermittent claudica-
tion and have >70% stenosis in iliac or femoral artery, stenting procedure was per-
formed after primary stenting or balloon angioplasty. Symptomatic patients withC224 JACC Vo>70% stenosis of popliteal or below-knee artery, balloon angioplasty was performed.
After the patients were followed up clinically.
Results: Tecnical success was achieved in 84 patients (98,8%). Predilatation before
stent placement, 33,3% of cases performed. Post dilation procedure was performed in
66,6% of patients with used the self-expanding stent. 84 patients with iliac-femoral
artery stenosis, stenting procedure is applied and concomitantly 6 patients with
popliteal artery and distal to the stenosis, the balloon angioplasty was performed.
Average follow-up time was 10,06,3 months. (1 – 25 Months). Including death,
myocardial infarction, major bleeding complications were not observed depending on
percutaneous procedures. Iliac stent in a patient as a complication inferior vena cava
ﬁstula formation, this complication was treated using a stent-graft. 7 patients with
diabetes and foot wounds that never heal, healed wounds were observed during
follow-up after the procedure. In the clinical follow-up, claudication complaints
decreased and increased walking distances observed.
Conclusıon: Technical success rate and early-midterm outcomes of percutaneous
treatment for PAD are magniﬁcent. We believe that percutaneous treatment methods
in lower extremity arterial stenosis, will be more widespread with percutaneous
treatment techniques and operator experience increases.PP-361
Percutaneous Closure of Patent Ductus Arteriosus: Experience of a Tertiary
Referral Center
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Objectıve: We sought to evaluate our clinical experience and short-term results of
percutaneous closure of patent ductus arteriosus (PDA).
Materıals-Methods: We studied 20 patients (17 female, mean age 248 years)
undergoing percutaneous closure of PDA between March 2010-March 2013 in our
clinic. Amplatzer duct occluder (ADO) I was used in 13 patients and ADO II was used
in 7 patients for PDA closure. Clinical charecteristics of patients, properties of
percutaneous closure intervention, complications and short-term results are evaluated.
Results: The mean ductus waist diameter measured by angiographic examination was
52 mm (2-9 mm). Procedure was successfully performed in all patients. Occluder
device embolization was occurred in one patient in whom device was retrieved by
snare catheter and PDA was successfully closed with same device. The early total
occlusion rate was 85%. Occlusion rate as determined by echocardiographic control
performed the day after was 95% whereas 100% at ﬁrst month. In the follow-up of
199 months, no complications were observed.
Conclusıon: Percutaneous closure of PDA using ADO I and II devices are safe and
effective.
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Purpose: Atherosclerosis is associated with the hemodynamic factors emerged from
the geometry of vessels outside of the traditional risk factors. When compared C and S
(sigma) shape of right coronary artery (RCA), C shape was found to be more asso-
ciated with coronary artery disease in previous studies. However, in patients admitted
with acute myocardial infarction(AMI) from the RCA, the effect of these two
geometric shape of RCA did not evaluated on TIMI frame count (TFC), distribution
and length of the lesion. The aim this study was to compare intracoronary ﬂow rates,
localization and severity of lesion between C and S shapes of RCA on coronary
angiography images by evaluation of angiographic images of primary percutaneous
interventions in AMI which is caused by RCA in our center.
Methods: The angiographic images of 163 of patients were evaluated who performed
primary percutaneous intervention due to AMI from RCA. Patients were divided into
two groups according to the geometric shape of RCA. Clinical and angiographic
parameters were compared in terms of C and S shapes of RCA.l 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTERS
